目的 探究复方活脑舒胶囊联合盐酸多奈哌齐片治疗轻中度阿尔茨海默病的临床疗效。方法 选取2013年1月-2018年1月南通大学附属海安医院收治的140名轻中度阿尔茨海默病患者作为研究对象，利用Excel表法随机分为对照组和治疗组，每组各70例。对照组患者口服盐酸多奈哌齐片，1片/次，1次/d。治疗组在对照组治疗的基础上口服复方活脑舒胶囊，3粒/次，2次/d。两组患者治疗周期均为6个月。观察两组患者的临床疗效，比较两组的简易智能状态量表（MMSE）评分、日常生活能力量表（ADL）评分、安静与认知负载刺激下的各频带脑电信号功率变化比值和不良反应。结果 治疗后，对照组和治疗组的总有效率分别为54.29%、91.43%，两组比较差异具有统计学意义（P<0.05）。治疗后，治疗组患者在安静与认知负载刺激下δ频带、θ频带均显著低于对照组，α1频带、α2频带、β1频带、β2频带均显著高于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组患者MMSE明显增高，ADL评分明显下降，同组治疗前后比较差异具有统计学意义（P<0.05）；治疗后，治疗组患者MMSE、ADL评分显著优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗期间，治疗组患者的不良反应发生率为7.14%，明显低于对照组的15.71%，两组比较差异具有统计学意义（P<0.05）。结论 复方活脑舒胶囊联合盐酸多奈哌齐片治疗轻中度阿尔茨海默病的临床疗效显著，可有效提高患者认知功能和日常生活能力，改善安静与认知负载刺激下的各频带脑电信号功率变化比值，具有一定的临床推广应用价值。

Objective To explore the clinical efficacy of Compound Huonaoshu Capsules combined with Donepezil Hydrochloride Tablets in treatment of mild and moderate Alzheimer's disease. Methods Patients (140 cases) with mild and moderate Alzheimer's disease in Haian Hospital Affiliated to Nantong University from January 2013 to January 2018 were randomly divided into control and treatment groups according to Excel Tablet method, and each group had 70 cases. Patients in the control group were po administered with Donepezil Hydrochloride Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Compound Huonaoshu Capsules on the basis of the control group, 3 grains/time, twice daily. Patients in two groups were treated for 6 month. After treatment, the clinical efficacy was evaluated, and MMSE scores, ADL scores, the ratios of power changes of EEG signals in different frequency bands with silent and cognitive load stimulation, and the adverse reactions in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 54.29% and 91.43%, respectively, and there was difference between two groups (P<0.05). After treatment, the δ frequency band and θ frequency band in the treatment group were significantly lower than those in the control group with silent and cognitive load stimulation, but α1, α2, β1, and β2 frequency band were higher than those in the control group, and there was difference between two groups (P<0.05). After treatment, MMSE scores in two groups was significantly increased, but ADL scores were significantly decreased, and there were differences in the same group (P<0.05). After treatment, MMSE scores and ADL scores in the treatment group were better than those in the control group, and there were differences between two groups (P<0.05). During the treatment, the incidence of adverse reaction in the treatment group was 7.14%, which was significantly lower than 15.71% in the control treatment group, with significant difference between two groups (P<0.05). Conclusion Compound Huonaoshu Capsules combined with Donepezil Hydrochloride Tablets has remarkable clinical efficacy in treatment of mild and moderate Alzheimer's disease, can effectively improve the cognitive function and daily living ability of patients, and improve the ratios of power changes of EEG signals in different frequency bands with silent and cognitive load stimulation, which has a certain clinical application value.